183 related articles for article (PubMed ID: 15664097)
1. Behavioral associations between prostate and colon cancer screening.
Carlos RC; Underwood W; Fendrick AM; Bernstein SJ
J Am Coll Surg; 2005 Feb; 200(2):216-23. PubMed ID: 15664097
[TBL] [Abstract][Full Text] [Related]
2. Demographics and health-related factors of men receiving prostate-specific antigen screening in Utah.
Merrill RM
Prev Med; 2001 Dec; 33(6):646-52. PubMed ID: 11716662
[TBL] [Abstract][Full Text] [Related]
3. Cancer screening among Latino subgroups in the United States.
Gorin SS; Heck JE
Prev Med; 2005 May; 40(5):515-26. PubMed ID: 15749133
[TBL] [Abstract][Full Text] [Related]
4. Associations of demographic and health-related characteristics with prostate cancer screening in Washington State.
Close DR; Kristal AR; Li S; Patterson RE; White E
Cancer Epidemiol Biomarkers Prev; 1998 Jul; 7(7):627-30. PubMed ID: 9681532
[TBL] [Abstract][Full Text] [Related]
5. Are we doing enough to screen for colorectal cancer? Findings from the 1999 Behavioral Risk Factor Surveillance System.
Seeff LC; Shapiro JA; Nadel MR
J Fam Pract; 2002 Sep; 51(9):761-6. PubMed ID: 12366896
[TBL] [Abstract][Full Text] [Related]
6. Cancer worry is associated with abnormal prostate-specific antigen levels in men participating in a community screening program.
Cohen L; Fouladi RT; Babaian RJ; Bhadkamkar VA; Parker PA; Taylor CC; Smith MA; Gritz ER; Basen-Engquist K
Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):610-7. PubMed ID: 12869399
[TBL] [Abstract][Full Text] [Related]
7. Factors influencing use of the prostate-specific antigen screening test in primary care.
Moran WP; Cohen SJ; Preisser JS; Wofford JL; Shelton BJ; McClatchey MW
Am J Manag Care; 2000 Mar; 6(3):315-24. PubMed ID: 10977432
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen test use reported in the 2000 National Health Interview Survey.
Ross LE; Coates RJ; Breen N; Uhler RJ; Potosky AL; Blackman D
Prev Med; 2004 Jun; 38(6):732-44. PubMed ID: 15193893
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer screening trends of New York State men at least 50 years of age, 1994 to 1997.
McDavid K; Melnik TA; Derderian H
Prev Med; 2000 Sep; 31(3):195-202. PubMed ID: 10964632
[TBL] [Abstract][Full Text] [Related]
10. Effect of physician recommendation and patient adherence on rates of colorectal cancer testing.
Brawarsky P; Brooks DR; Mucci LA; Wood PA
Cancer Detect Prev; 2004; 28(4):260-8. PubMed ID: 15350629
[TBL] [Abstract][Full Text] [Related]
11. The impact of informed consent on patient interest in prostate-specific antigen screening.
Wolf AM; Nasser JF; Wolf AM; Schorling JB
Arch Intern Med; 1996 Jun; 156(12):1333-6. PubMed ID: 8651843
[TBL] [Abstract][Full Text] [Related]
12. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.
Andriole GL; Levin DL; Crawford ED; Gelmann EP; Pinsky PF; Chia D; Kramer BS; Reding D; Church TR; Grubb RL; Izmirlian G; Ragard LR; Clapp JD; Prorok PC; Gohagan JK;
J Natl Cancer Inst; 2005 Mar; 97(6):433-8. PubMed ID: 15770007
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with perceived risk in automotive employees at increased risk of colorectal cancer.
Vernon SW; Myers RE; Tilley BC; Li S
Cancer Epidemiol Biomarkers Prev; 2001 Jan; 10(1):35-43. PubMed ID: 11205487
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with men's use of prostate-specific antigen screening: evidence from Health Information National Trends Survey.
Finney Rutten LJ; Meissner HI; Breen N; Vernon SW; Rimer BK
Prev Med; 2005 Apr; 40(4):461-8. PubMed ID: 15530599
[TBL] [Abstract][Full Text] [Related]
15. Adherence to an annual PSA screening program over 3 years for brothers and sons of men with prostate cancer.
Roumier X; Azzouzi R; Valéri A; Guillemin F; Fournier G; Cussenot O; Mangin P; Cormier L
Eur Urol; 2004 Mar; 45(3):280-5; author reply 285-6. PubMed ID: 15036671
[TBL] [Abstract][Full Text] [Related]
16. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Schröder FH
Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
[TBL] [Abstract][Full Text] [Related]
17. Female gender and other factors predictive of a limited screening flexible sigmoidoscopy examination for colorectal cancer.
Eloubeidi MA; Wallace MB; Desmond R; Farraye FA
Am J Gastroenterol; 2003 Jul; 98(7):1634-9. PubMed ID: 12873591
[TBL] [Abstract][Full Text] [Related]
18. Evidence of prostate cancer screening in a UK region.
Gavin A; McCarron P; Middleton RJ; Savage G; Catney D; O'Reilly D; Keane PF; Murray LJ
BJU Int; 2004 Apr; 93(6):730-4. PubMed ID: 15049981
[TBL] [Abstract][Full Text] [Related]
19. Will men attribute fault to their GP for adverse effects arising from controversial screening tests? An Australian study using scenarios about PSA screening.
Gattellari M; Ward JE
J Med Screen; 2004; 11(4):165-9. PubMed ID: 15563771
[TBL] [Abstract][Full Text] [Related]
20. Increasing level of prostate-specific antigen and prostate cancer risk factors among 193 men examined in screening procedure.
Opalińska E; Michalak A; Stoma F; Latalski M; Goniewicz M
Ann Univ Mariae Curie Sklodowska Med; 2003; 58(2):57-63. PubMed ID: 15323167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
